Allo-SCT using reduced-intensity conditioning against advanced pancreatic cancer

A Japanese survey

Y. Kanda, Y. Omuro, Eishi Baba, K. Oshima, K. Nagafuji, Y. Heike, Y. Takaue, T. Sasaki, H. Sakamaki, M. Harada

研究成果: ジャーナルへの寄稿記事

7 引用 (Scopus)

抄録

Pancreatic cancer is a frequent cause of cancer-related mortality and has an extremely poor prognosis. To evaluate the efficacy of allogeneic hematopoietic SCT with reduced-intensity conditioning (RICT) against pancreatic cancer, we analyzed the clinical data of 22 patients. After a fludarabine-based conditioning regimen followed by the infusion of PBSCs, all but two achieved engraftment. Complete, partial and minor response was observed in 1, 2 and 2 patients, respectively, with an overall response rate of 23%. Median survival was only 139 days and the major cause of death was tumor progression. Poor performance status before RICT and a lower number of infused CD34-positive cells were associated with shorter survival after RICT. Patients who developed chronic GVHD tended to survive longer than those who did not. These findings support the investigation of a novel treatment strategy to enhance the immunological effect against pancreatic cancer.

元の言語英語
ページ(範囲)99-103
ページ数5
ジャーナルBone Marrow Transplantation
42
発行部数2
DOI
出版物ステータス出版済み - 7 1 2008

Fingerprint

Pancreatic Neoplasms
Survival
Cause of Death
Neoplasms
Mortality
Surveys and Questionnaires
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

これを引用

Allo-SCT using reduced-intensity conditioning against advanced pancreatic cancer : A Japanese survey. / Kanda, Y.; Omuro, Y.; Baba, Eishi; Oshima, K.; Nagafuji, K.; Heike, Y.; Takaue, Y.; Sasaki, T.; Sakamaki, H.; Harada, M.

:: Bone Marrow Transplantation, 巻 42, 番号 2, 01.07.2008, p. 99-103.

研究成果: ジャーナルへの寄稿記事

Kanda, Y, Omuro, Y, Baba, E, Oshima, K, Nagafuji, K, Heike, Y, Takaue, Y, Sasaki, T, Sakamaki, H & Harada, M 2008, 'Allo-SCT using reduced-intensity conditioning against advanced pancreatic cancer: A Japanese survey', Bone Marrow Transplantation, 巻. 42, 番号 2, pp. 99-103. https://doi.org/10.1038/bmt.2008.94
Kanda, Y. ; Omuro, Y. ; Baba, Eishi ; Oshima, K. ; Nagafuji, K. ; Heike, Y. ; Takaue, Y. ; Sasaki, T. ; Sakamaki, H. ; Harada, M. / Allo-SCT using reduced-intensity conditioning against advanced pancreatic cancer : A Japanese survey. :: Bone Marrow Transplantation. 2008 ; 巻 42, 番号 2. pp. 99-103.
@article{e8af355260684c06a8a587a6c9c7c8a1,
title = "Allo-SCT using reduced-intensity conditioning against advanced pancreatic cancer: A Japanese survey",
abstract = "Pancreatic cancer is a frequent cause of cancer-related mortality and has an extremely poor prognosis. To evaluate the efficacy of allogeneic hematopoietic SCT with reduced-intensity conditioning (RICT) against pancreatic cancer, we analyzed the clinical data of 22 patients. After a fludarabine-based conditioning regimen followed by the infusion of PBSCs, all but two achieved engraftment. Complete, partial and minor response was observed in 1, 2 and 2 patients, respectively, with an overall response rate of 23{\%}. Median survival was only 139 days and the major cause of death was tumor progression. Poor performance status before RICT and a lower number of infused CD34-positive cells were associated with shorter survival after RICT. Patients who developed chronic GVHD tended to survive longer than those who did not. These findings support the investigation of a novel treatment strategy to enhance the immunological effect against pancreatic cancer.",
author = "Y. Kanda and Y. Omuro and Eishi Baba and K. Oshima and K. Nagafuji and Y. Heike and Y. Takaue and T. Sasaki and H. Sakamaki and M. Harada",
year = "2008",
month = "7",
day = "1",
doi = "10.1038/bmt.2008.94",
language = "English",
volume = "42",
pages = "99--103",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Allo-SCT using reduced-intensity conditioning against advanced pancreatic cancer

T2 - A Japanese survey

AU - Kanda, Y.

AU - Omuro, Y.

AU - Baba, Eishi

AU - Oshima, K.

AU - Nagafuji, K.

AU - Heike, Y.

AU - Takaue, Y.

AU - Sasaki, T.

AU - Sakamaki, H.

AU - Harada, M.

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Pancreatic cancer is a frequent cause of cancer-related mortality and has an extremely poor prognosis. To evaluate the efficacy of allogeneic hematopoietic SCT with reduced-intensity conditioning (RICT) against pancreatic cancer, we analyzed the clinical data of 22 patients. After a fludarabine-based conditioning regimen followed by the infusion of PBSCs, all but two achieved engraftment. Complete, partial and minor response was observed in 1, 2 and 2 patients, respectively, with an overall response rate of 23%. Median survival was only 139 days and the major cause of death was tumor progression. Poor performance status before RICT and a lower number of infused CD34-positive cells were associated with shorter survival after RICT. Patients who developed chronic GVHD tended to survive longer than those who did not. These findings support the investigation of a novel treatment strategy to enhance the immunological effect against pancreatic cancer.

AB - Pancreatic cancer is a frequent cause of cancer-related mortality and has an extremely poor prognosis. To evaluate the efficacy of allogeneic hematopoietic SCT with reduced-intensity conditioning (RICT) against pancreatic cancer, we analyzed the clinical data of 22 patients. After a fludarabine-based conditioning regimen followed by the infusion of PBSCs, all but two achieved engraftment. Complete, partial and minor response was observed in 1, 2 and 2 patients, respectively, with an overall response rate of 23%. Median survival was only 139 days and the major cause of death was tumor progression. Poor performance status before RICT and a lower number of infused CD34-positive cells were associated with shorter survival after RICT. Patients who developed chronic GVHD tended to survive longer than those who did not. These findings support the investigation of a novel treatment strategy to enhance the immunological effect against pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=48349144906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48349144906&partnerID=8YFLogxK

U2 - 10.1038/bmt.2008.94

DO - 10.1038/bmt.2008.94

M3 - Article

VL - 42

SP - 99

EP - 103

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 2

ER -